Hemostemix (HEM) Price & Analysis

Compare

20 Followers

HEM Stock Chart & Stats

C$0.08

C$0.03(23.81%)

At close: Jan 08 4:00 PM EST

C$0.08

C$0.03(23.81%)

Day’s Range― - ―

52-Week RangeC$0.07 - C$0.31

Previous CloseN/A

Volume356.00K

Average Volume (3M)138.35K

Market Cap

C$16.96M

Enterprise ValueC$19.25M

Total Cash (Recent Filing)C$1.30M

Total Debt (Recent Filing)C$3.44M

Price to Earnings (P/E)―

Beta0.25

Next Earnings

May 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding188,488,540

10 Day Avg. Volume155,944

30 Day Avg. Volume138,348

Financial Highlights & Ratios

PEG Ratio0.47

Price to Book (P/B)-1.58

Price to Sales (P/S)0.00

P/FCF Ratio-6.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Funding For Product DevelopmentThe recent funding will enhance Hemostemix's ability to advance its stem cell therapeutics platform, supporting long-term product development and commercialization efforts.

Commitment To InnovationInvestment in ACP processing underscores Hemostemix's commitment to innovation, which is crucial for long-term success in the competitive biotechnology industry.

Strategic Focus On Stem Cell TherapiesHemostemix's focus on stem cell therapies positions it well in the regenerative medicine field, addressing unmet medical needs and potentially capturing significant market share.

Bears Say

Lack Of Revenue GenerationThe absence of revenue generation highlights significant challenges in achieving profitability, necessitating strategic realignment for financial sustainability.

Cash Flow ChallengesNegative cash flows suggest reliance on external financing, which can strain resources and hinder strategic initiatives if not addressed.

Financial InstabilityHigh leverage and negative equity indicate financial instability, limiting Hemostemix's ability to invest in growth and posing risks to long-term sustainability.

Hemostemix News

Hemostemix Raises C$480,000 to Advance Stem Cell Therapy Commercialization

An announcement from Hemostemix ( ($TSE:HEM) ) is now available. Hemostemix has raised C$480,000 through a non-brokered private...

1M ago

Hemostemix Grants Stock Options to Boost Growth

Hemostemix ( ($TSE:HEM) ) has issued an update. Hemostemix Inc. announced the granting of 963,000 stock options to...

2M ago

Hemostemix Highlights VesCell Success at DFCon 2025 and Secures New Funding

Hemostemix ( ($TSE:HEM) ) just unveiled an update. Hemostemix announced its participation in DFCon 2025, a leading conference...

2M ago

Hemostemix Secures CDN$280,594 Private Placement for Operational Growth

Hemostemix ( ($TSE:HEM) ) has shared an update. Hemostemix Inc. announced the conditional approval of its CDN$280,594 private...

3M ago

Hemostemix Closes $461,230 Private Placement to Boost Operations

Hemostemix ( ($TSE:HEM) ) has issued an announcement. Hemostemix Inc. announced the closing of its first tranche of...

3M ago

Hemostemix Secures TSXV Approval for Debt Settlement

Hemostemix ( ($TSE:HEM) ) has issued an update. Hemostemix Inc. announced the approval of a debt settlement by...

5M ago

Hemostemix Announces Strategic Private Placement to Enhance Operations

Hemostemix ( ($TSE:HEM) ) has shared an announcement. Hemostemix Inc., a leader in autologous stem cell therapy, announced...

5M ago

Hemostemix Expands Private Placement to $3 Million

Hemostemix ( ($TSE:HEM) ) has provided an announcement. Hemostemix Inc. has increased its previously closed non-brokered private placement...

6M ago

Hemostemix Advances with Successful Sale of Convertible Debentures

The latest update is out from Hemostemix ( ($TSE:HEM) ). Hemostemix Inc. has announced the closing of the...

6M ago

Hemostemix Secures $2.97 Million in Private Placement to Boost Operations

Hemostemix ( ($TSE:HEM) ) has provided an update. Hemostemix Inc. has successfully closed a non-brokered private placement, raising...

7M ago

HEM FAQ

What was Hemostemix Inc’s price range in the past 12 months?

Hemostemix Inc lowest stock price was C$0.07 and its highest was C$0.30 in the past 12 months.

What is Hemostemix Inc’s market cap?

Hemostemix Inc’s market cap is C$16.96M.

When is Hemostemix Inc’s upcoming earnings report date?

Hemostemix Inc’s upcoming earnings report date is May 05, 2026 which is in 89 days.

How were Hemostemix Inc’s earnings last quarter?

Hemostemix Inc released its earnings results on Nov 28, 2025. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.

Is Hemostemix Inc overvalued?

According to Wall Street analysts Hemostemix Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Hemostemix Inc pay dividends?

Hemostemix Inc does not currently pay dividends.

What is Hemostemix Inc’s EPS estimate?

Hemostemix Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Hemostemix Inc have?

Hemostemix Inc has 188,488,540 shares outstanding.

What happened to Hemostemix Inc’s price movement after its last earnings report?

Hemostemix Inc reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Hemostemix Inc?

Currently, no hedge funds are holding shares in TSE:HEM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Hemostemix Inc

Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.